Summary

Overview
Global eosinophilic esophagitis treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Eosinophilic esophagitis (EoE) is a chronic allergic or immune disorder of the digestive system in which large numbers of white blood cells called eosinophils are present in the esophagus. It causes an inflammation of the esophagus caused by an overabundance of certain white blood cells. Food allergies are thought to be one cause of the condition. This condition is characterized by vomiting, stomach or chest pain, failure to thrive (particularly in children), difficulty swallowing and food getting stuck in the throat.
Eosinophilic esophagitis has no cure, but certain medicines, such as corticosteroids such as budesonide and fluticasone propionate, proton pump inhibitors such as omeprazole, pantoprazole, esomeprazole, rabeprazole and others, and eliminating specific foods such as dairy products, eggs, wheat, soy, peanut, tree nuts, and fish from the diet can help reduce the redness and swelling in the esophagus.
Market Dynamics: Drivers
Increasing adoption of innovative therapeutics
The increasing adoption of innovative therapeutics is expected to drive the global market over the forecast period. The innovative therapeutics for the treatment of eosinophilic esophagitis aim to address the unmet needs associated with the management and treatment of the disease and its associated complications by providing alternative or complementary treatment options for better disease treatment and better patient outcomes.
For instance, on September 26, 2023, Regeneron Pharmaceuticals, Inc. and Sanofi cleared that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application for Dupixent (dupilumab) to treat children aged 1 to 11 years with eosinophilic esophagitis (EoE).
Moreover, many clinical trials are going on for the development of novel therapeutics that show better results in eosinophilic esophagitis treatment. For instance, on October 12, 2022, Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company with an innovative drug delivery technology platform, released the initiation of a Phase 2 trial of EP-104IAR in adult patients afflicted with eosinophilic esophagitis (EoE), a rare disease that restricts the ability to swallow food and greatly impacts the quality of life.
In Addition, the regulatory approvals for the development of innovative therapeutics increase the trust in patients about the development of novel therapeutics. For instance, on 8 October 2021, Tezepelumab was granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen and is under Priority Review for patients with asthma in the US.
Further, the increasing prevalence of eosinophilic esophagitis (EoE), rising regulatory approvals such as FDA approvals, increasing clinical trials, increasing awareness about the availability of treatment options and technological advancements in developing novel drugs and therapies are expected to drive the market over the forecast period.
Restraints
Factors such as complications associated with the use of corticosteroids and other drugs, the high cost of the treatment of eosinophilic esophagitis (EoE) and the lack of better and appropriate therapeutics for the treatment are expected to hamper the market.
Segment Analysis
The global eosinophilic esophagitis (EoE) treatment market is segmented based on treatment type, route of administration, distribution channel and region.
The corticosteroids segment accounted for approximately 51.1% of the eosinophilic esophagitis (EoE) treatment market share
The corticosteroids segment is expected to hold the largest market share over the forecast period. Usually, there is no cure for eosinophilic esophagitis (EoE), but corticosteroids such as budesonide and fluticasone propionate are most commonly used and are considered first-line therapeutics for the management of this condition. Corticosteroids constitute the mainstay of EoE treatment and are frequently used as first-line agents once an EoE is confirmed. Corticosteroids decrease eosinophil mucosal migration by inhibiting cytokines, leading to reduced remodeling and tissue fibrosis.
For instance, on February 8, 2021, Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company, released that APT-1011 (fluticasone propionate oral disintegrating tablet) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of Eosinophilic Esophagitis (EoE).
Additionally, on December 15, 2020, Takeda Pharmaceutical Company Limited cleared that the United States (U.S.) Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application and granted Priority Review for the investigational therapy budesonide oral suspension, TAK-721, which has been designed specifically for eosinophilic esophagitis (EoE). If approved, TAK-721 will be the first FDA-approved treatment for chronic inflammatory disease, and Takeda plans to use the trade name Eohilia (budesonide oral suspension).
Further, topical corticosteroids are most commonly preferred and their wide availability, acceptability, and ease of application helps to hold the largest market share. The corticosteroids can also used by combining with other drugs, these combining drugs are considered especially in cases where a single drug modality may not be sufficient. In addition, their wide adoption also increases the demand for the corticosteroids.
Geographical Analysis
North America accounted for approximately 39.2% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare facilities. North America especially the United States is very well-known for its strong presence of major players such as pharmaceutical companies and biotechnology companies. The presence of major players actively performing in clinical trials and research activities leads to the launch of novel therapeutics for the treatment of eosinophilic esophagitis.
For instance, on December 21, 2021, Allakos Inc., a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, reported data from KRYPTOS, a 24-week Phase 2/3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy-confirmed eosinophilic esophagitis (EoE).
Furthermore, the region is also known for its advanced healthcare infrastructure such as hospitals, specialty clinics and research centers, which provide advanced healthcare facilities for the treatment of eosinophilic esophagitis. The region’s advanced healthcare infrastructure actively performs the research activities, as the research activities increase, the therapeutics are developed more precisely by reducing the adverse effects and complications associated with the therapeutics, which results in better patient outcomes.
Competitive Landscape
The major global players in the eosinophilic esophagitis (EoE) treatment market include Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Regeneron Pharmaceuticals, Inc., Revolo Biotherapeutics, Landos Biopharma, Inc., Sanofi SA, Curia Global, Inc., Cadila Pharmaceuticals, Pfizer Inc., Dr. Reddy’s Laboratories Ltd. and among others.
Key Developments
• On May 20, 2022, EsoCap AG, the Swiss biotech company dedicated to improving the lives of patients with serious diseases of the upper gastrointestinal tract, is supporting the first European EoE day launched on 22 May 2022 initiated by EUROS (European Society of Eosinophilic Oesophagitis) and AEDESEO, the Spanish association of EoE patients. The campaign is the first of its kind in Europe and highlights the need for more public information about eosinophilic esophagitis in general and more specifically, about EoE diagnosis and treatment pathways.
• On April 06, 2021, Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, released that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for omilancor (BT-11), a novel, orally administered, gut-restricted LANCL2 agonist, in development for the treatment of Eosinophilic Esophagitis (EoE).
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global eosinophilic esophagitis (EoE) treatment market. The pandemic affected the initiation and conduct of clinical trials and research activities for the development of novel therapeutics and are temporarily disrupted due to the redirected focus on the COVID-19 pandemic. The pandemic also disrupted the supply chain of these treatment drugs globally.
Market Segmentation
By Treatment Type
• Proton Pump Inhibitors
o Omeprazole
o Pantoprazole
o Esomeprazole
o Rabeprazole
o Others
• Corticosteroids
o Budesonide
o Fluticasone Propionate
o Others
• Others
By Route of Administration
• Oral
• Topical
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Why Purchase the Report?
• To visualize the global eosinophilic esophagitis (EoE) treatment market segmentation based on treatment type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of eosinophilic esophagitis (EoE) treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global eosinophilic esophagitis (EoE) treatment market report would provide approximately 61 tables, 57 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents